Epistem Share Discussion Threads

[ladyfarmer] 05/7/2012 08:16

Great news! How many TB tests in India?
Epistem Holdings plc Tuberculosis test gains CE-IVD registration
Date : 05/07/2012 @ 07:00
Source : UK Regulatory (RNS & others)
Stock : Epistem (EHP)
Quote : 400.0 0.0 (0.00%) @ 05:00
HOME » LSE » E » Epistem share price
Free Epistem Annual Company Report

Epistem Holdings plc Tuberculosis test gains CE-IVD registration
Share this article PrintAlert
TIDMEHP
RNS Number : 9465G
Epistem Holdings plc
05 July 2012
Epistem Plc
("Epistem" or "the Company")
Epistem Tuberculosis test gains CE-IVD registration
Epistem (London AIM:EHP), the biotechnology and personalised medicine company, is pleased to announce the registration of its rapid molecular test for Tuberculosis (TB) test as a CE Marked in-vitro diagnostic medical device (CE-IVD). The registration enables Epistem and/or its authorised representatives to place its TB test and Genedrive(TM)units for sale in the EEA member state markets.
Genedrive(TM) provides a major advance in next generation molecular diagnostic testing by providing a rapid (30 minute), low cost, simple to use 'Point of Care' device with high sensitivity and specificity. Genedrive(TM) has applications across a wide range of bacterial, viral and fungal and somatic mutation disease status. Genedrive(TM) will be targeted at providing 'gold standard' identification of Mycobacterium tuberculosis and antibiotic resistance testing and will be priced competitively with traditional less reliable methods of diagnosis such as microscopy and culturing. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs.
On the back of this CE-IVD registration, Epistem is now preparing regulatory submissions for India in advance of the anticipated launch of its first molecular TB test including patient assessment for antibiotic resistance towards the end of this year.
India has the largest number of TB sufferers in the world, more than twice the number in China, which has the second highest infection rate. According to the WHO, every year 2 million new patients in India develop TB, with the highest incidence of fatalities occurring in remote rural areas.
Commenting on the successful registration of Epistem's first Genedrive(TM) test, Matthew Walls, CEO said "This is an important milestone for the Company as we move towards our first significant revenue stream in the commercialization of Genedrive(TM)"
For further information contact:
Epistem Plc
Matthew Walls, Chief Executive Officer ++44 161 606 7258
Peel Hunt LLP
Nominated Adviser: James Steel/Vijay Barathan ++44 207 418 8900
De Facto Financial
Mike Wort/Anna Dunphy ++44207 556 1063
Notes for editors
Epistem is a biotechnology company commercialising its expertise in stem cells in the areas of epithelial (oncology, gastrointestinal and dermatological) and infectious diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics (Genedrive(TM)) alongside contract research services to drug development companies. The Group's core expertise is focused around the regulation of adult stem cells located in epithelial tissue including the gastrointestinal tract, skin, hair follicles, breast and prostate and utilizing novel and proprietary next generation molecular biology for use in personalised medicine. www.epistem.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSSUFILFESEIW

Epistem (LSE:EHP)
Historical Stock Chart
1 Year : From Jul 2011 to Jul 2012
Epistem (LSE:EHP)
Intraday Stock Chart
Today : Thursday 5 July 2012

[ladyfarmer] 05/7/2012 08:16

Great news! How many TB tests in India?
Epistem Holdings plc Tuberculosis test gains CE-IVD registration
Date : 05/07/2012 @ 07:00
Source : UK Regulatory (RNS & others)
Stock : Epistem (EHP)
Quote : 400.0 0.0 (0.00%) @ 05:00
HOME » LSE » E » Epistem share price
Free Epistem Annual Company Report

Epistem Holdings plc Tuberculosis test gains CE-IVD registration
Share this article PrintAlert
TIDMEHP
RNS Number : 9465G
Epistem Holdings plc
05 July 2012
Epistem Plc
("Epistem" or "the Company")
Epistem Tuberculosis test gains CE-IVD registration
Epistem (London AIM:EHP), the biotechnology and personalised medicine company, is pleased to announce the registration of its rapid molecular test for Tuberculosis (TB) test as a CE Marked in-vitro diagnostic medical device (CE-IVD). The registration enables Epistem and/or its authorised representatives to place its TB test and Genedrive(TM)units for sale in the EEA member state markets.
Genedrive(TM) provides a major advance in next generation molecular diagnostic testing by providing a rapid (30 minute), low cost, simple to use 'Point of Care' device with high sensitivity and specificity. Genedrive(TM) has applications across a wide range of bacterial, viral and fungal and somatic mutation disease status. Genedrive(TM) will be targeted at providing 'gold standard' identification of Mycobacterium tuberculosis and antibiotic resistance testing and will be priced competitively with traditional less reliable methods of diagnosis such as microscopy and culturing. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs.
On the back of this CE-IVD registration, Epistem is now preparing regulatory submissions for India in advance of the anticipated launch of its first molecular TB test including patient assessment for antibiotic resistance towards the end of this year.
India has the largest number of TB sufferers in the world, more than twice the number in China, which has the second highest infection rate. According to the WHO, every year 2 million new patients in India develop TB, with the highest incidence of fatalities occurring in remote rural areas.
Commenting on the successful registration of Epistem's first Genedrive(TM) test, Matthew Walls, CEO said "This is an important milestone for the Company as we move towards our first significant revenue stream in the commercialization of Genedrive(TM)"
For further information contact:
Epistem Plc
Matthew Walls, Chief Executive Officer ++44 161 606 7258
Peel Hunt LLP
Nominated Adviser: James Steel/Vijay Barathan ++44 207 418 8900
De Facto Financial
Mike Wort/Anna Dunphy ++44207 556 1063

[l2user] 06/1/2012 11:29

ImmuPharma, Shire, ReNeuron and Epistem make it into Merchant's top 12 for 2012
11:12 am by Ian Lyall

[lucky_punter] 03/11/2011 11:30

One of the risks investors in early-stage life science firms often need to be wary of is that a company, at some point, will come back to them for more cash in order to fund the next stage of their development. Epistem (LON:EHP) is a biotechnology company that goes some way to obviating this by combining a cash-generative contract research business in order to fund its own research activities.

[lucky_punter] 11/10/2011 14:17

Stem cell technology firm Epistem Holdings (LON:EHP) said today that a strengthening operational and financial position confirms its belief that the year ahead will continue to generate substantial increases in its forecast revenues.

Broker Peel Hunt said that a key driver for the firm will be Epistem's Genedrive molecular diagnostic device.

[aim_trader] 10/12/2010 09:31

Asph - agree 100%.

Watch this:

Matthew Walls of EpiStem says all 3 of his company's divisions will show growth in 2011

Friday, December 10, 2010

Matthew Walls, CEO of EpiStem Plc, tells Proactive Investors that while the Personalised Medicine division will show the biggest growth in 2011 both Novel Therapies and Contract Research are also set for solid growth. Matthew says he is actively looking for acquisitions to either create a 4th division or complement the existing ones.

[asph] 03/11/2010 14:19

Excellent news today ---they are so well established with their financial supporters.
keeping an eye -- in fact adding to holding --- but please DYOR first

[andy] 06/10/2010 23:36

Great new article by Proactive!

[ceohunter] 21/4/2010 08:26

If you would like to see EpiStem's presentation from last night's Proactiveinvestors One2One Forum please follow this link:

[asph] 19/4/2010 11:28

Anyone attending Pro Active Investors forum tomorrow ? I am stuck by grounded aircraft-----------shall be pleased if you can update this thread following that meeting-with thanks

[ceohunter] 06/4/2010 11:59

The directors of Rexahn Pharmaceuticals (AMEX: RNN), Asterand (LSE: ATD), Alliance Pharma plc (AIM: APH) and EpiStem Holdings Plc (AIM: EHP) will be presenting on:

Tuesday the 20th April 2010
at the
Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

The presentations will start at 6:00pm and finish at approx 8.00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception.

[asph] 10/3/2010 08:19

Half Year results are sound and further price enhancement assured as this one becomes recognised

[asph] 10/3/2010 08:17

Half Year results are sound and further price enhancement assured as this one becomes recognised

[tomesy27] 15/12/2009 10:56

Epistem: Novartis collaboration puts therapeutic and biomarker cancer specialist on the map

Epithelial cancers account for more than 80% of adult cancers, so there is a well-defined market for Epistem's therapeutic products and diagnostic biomarkers in this area.

[andy] 14/12/2009 11:02

Great new article by proactiveinvestors.co.uk!

[ceohunter] 04/12/2009 16:00

To view Epistem's presentation at the Proactive Investors One2One Forum yesterday evening please follow this link:

[ceohunter] 26/11/2009 09:32

The directors of Epistem (AIM: EHP), Access Pharmaceuticals (OTCBB: ACCP) and Biocompatibles (LSE: BII) will be presenting:

Thursday the 3rd December 2009
Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

The presentations will start at 6:00pm and finish at approx 7:30pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception.

[aim_trader] 25/11/2009 18:52

a song comes to mind... "the only way is up... baby..."...

[zagrem] 20/11/2009 12:26

I'll settle for £5; rare share and peace and quiet board that doubles/triples with no fuss but a little patience. Still here Yuka.

[yuka] 20/11/2009 11:17

See they have just done a placing of new shares at 400 to raise more money for furthe expansion. Share price taken it rather well. Onward and upward. £10 by Christmas :)